{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-23-000010","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.513293+00:00","generated_at":"2026-06-16T05:52:25.503599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vertex Q1 product rev $2.37B (+13%); net income down 8% on higher R&D; FY23 guidance unchanged","bullets":["Product revenue $2.37B (+13% YoY); U.S. $1.40B (+3%), ex-U.S. $971M (+33%).","GAAP net income decreased 8% YoY; cash and marketable securities $11.5B at quarter end.","FY23 product revenue guidance reaffirmed at $9.55-9.7B; combined GAAP R&D and SG&A unchanged at $4.35-4.6B.","TRIKAFTA approved in U.S. for CF children aged 2-5; completed rolling BLA submissions for exa-cel in U.S.","Pipeline: VX-548 acute pain Phase 3 enrollment ongoing; inaxaplin AMKD Phase 2/3; VX-880 T1D data expected at ADA June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-23-000010","json":"https://secwatch.observer/filing/0000875320-23-000010.json","markdown":"https://secwatch.observer/filing/0000875320-23-000010.md","text":"https://secwatch.observer/filing/0000875320-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000010/0000875320-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000010/vrtx-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:52:25.503599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb814de2e1e21d4fe98bff180cbe7fbab1872d35","claim":"VERTEX PHARMACEUTICALS INC / MA reported the first quarter ended March 31, 2023 results: revenue $2.37 billion. Guidance reaffirmed.","evidence_excerpt":"as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2023 Financial Results — Product revenue of $2.37 billion, a 13% increase compared to Q1 2022 — — Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion — — TRIKAFTA approved in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000010/0000875320-23-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2.37 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}